RxDoctor Payments Data

Lily Hipp, MD

Ophthalmology · Savannah, GANPI 1548764947

Payments from drug & device makers

$6,864in general payments, 2019–2025

Across 94 payments — averaging $73.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$2K
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$2K
  • AbbVie$1K
  • Glaukos Corporation$795
  • Rayner Intraocular Lenses Limited$144
  • NEW World Medical,inc.$138
  • plus $823 from 10 others

What the payments were for

  • Travel & lodging$2,26533%
  • Food & beverage$4,59967%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,864 in reported general payments places this provider in the 75th percentile of 481 ophthalmology providers in Georgia.

See all ophthalmology providers in Georgia

Medicare billing

Part B allowed, 2024
$86,787
Medicare patients
167
Services billed
876

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RhopressaNetarsudil Mesylate30$10,755
RocklatanNetarsudil Mesylat/Latanoprost19$8,225
LumiganBimatoprost14$7,092
RestasisCyclosporine11$6,600
Prednisolone Acetate124$6,193
SimbrinzaBrinzolamide/Brimonidine Tart16$3,453
Alphagan PBrimonidine Tartrate13$3,023
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol13$2,832
MoxifloxacinMoxifloxacin Hcl93$2,205
Brinzolamide11$2,117
Latanoprost231$2,056
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat166$1,894
Travoprost12$1,568
Timolol Maleate59$1,026
Atropine Sulfate29$969

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis, Alphagan P$1,079$16,71538 claims
AlconSimbrinza$2,172$3,45316 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 481 ophthalmology providers in Georgia.

Other ophthalmology in Savannah

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →